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vital role in the signal transduction of cancers. Hsp90 inhibitors are able to inhibit Hsp90 or the
complex of Hsp90 and co-chaperones resulting in the degradation of Hsp90-dependent client
proteins through the ubiquitination-proteasome pathway, thereby leading to the growth inhibition
of tumor cells. This review will brieﬂy discuss the molecular structure and biological function of
Hsp90, and focus on a summary of recent progress in the development and testing of natural Hsp90
inhibitors and their different means by which they interact with Hsp90.
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Table 1 Relationship between Hsp90 client proteins and
hallmarks of cancer.
Hallmark of cancer Hsp90 client protein
Evasion of apoptosis Akt,Rip,P53,Survivin,
Apaf-1,Bcl-2,IGF-IR
Sustained angiogenesis VEGFR, HIF1,Akt,
Fit-3,FAK,Src
Limitless replicative potential n-TERT, telomerase
Tissue invasion and metastasis c-MET,MMP2
Self-sufﬁciency in growth signals EGFR/Her-2,Raf,
Bcr-Abl,ErbB-2,
Src,Akt,MEK
Insensitivity to anti-growth
signals
Plk-1,Cdk4,Cdk6,
Myt-1,cyclin D
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Heat shock proteins (Hsps) are a family of highly conserved
stress proteins which can be induced by environmental stress
such as heat, hypoxia, DNA damage or UV radiation to
regulate cell metabolism and protect prokaryotic and eukar-
yotic cells from harmful exogenous stimulation. They are also
known as molecular chaperones due to their ability to
maintain proper protein folding, and facilitate the assembly
of protein polymers and the formation of mature proteins.
The highly conserved molecular chaperone Hsp90 is one of
the most abundant of proteins in almost all eukaryotic cells,
accounting for 1–2% of total cellular proteins1. Hsp90 has two
major cytoplasmic isoforms Hsp90a (inducible form) and
Hsp90b (constitutive form), as well as a Raf-associated protein
Hsp90N which is associated with cellular transformation2.
Other Hsp90 analogues include glucose regulated protein 94
(Grp94) in the endoplasmic reticulum and tumor necrosis
factor receptor-associated protein 1 (TRAP1) in the mitochon-
drial matrix1,2.
Hsp90, in general, exists as a homodimer (a/a or b/b) in
cells. The structure of Hsp90 is composed of three domains:
the highly conserved NH2-terminal nucleotide binding domain
(25 kDa, Hsp90N), the middle domain (35 kDa, Hsp90M) and
the C-terminal domain (10 kDa, Hsp90C). Hsp90N is an
important binding site for ATP/ADP, which is associated
with forming the complex of Hsp90 and co-chaperones via
conformational transition3. Hsp90M is the binding site for
nuclear localization signal and client proteins, and is involved
in the speciﬁc recognition of client proteins and regulating
molecular chaperones for appropriate substrate activation
including ATP hydrolysis4. The C-terminal of Hsp90 is the
site of dimerization. This region contains a pentapeptide
domain (MEEVD) which is also the binding site of co-
chaperones of Hsp90 such as Hop and Sti 15.
In eukaryotic plasma, Hsp90 is considered to mediate the
folding, stabilization, activation and assembly of its client
proteins, including steroid receptors, protein kinases and
transcription factors, through the formation of complexes with
other co-chaperones such as Hsp70, Hop and p236. A client
protein is bound to Hsp70/Hsp40 to form an early complex,
and then Hsp90 along with the co-chaperone Hop binds to this
early complex to form an intermediate complex. When ADP is
replaced by ATP, Hsp90 undergoes a conformational change
which releases Hsp70/Hsp40 and Hop, thus allowing the ATP-
dependent association of other co-chaperones, including p23
and the immunophilins to form a mature complex. When the
ATP-binding site of Hsp90 is occupied by competitive inhibi-
tors, the Hsp90 complex is disrupted and the client proteins can
be degraded through the ubiquitination-proteasome pathway6,7.
Cancer is a disease associated with genetic instability which
allows cancer cells to acquire six distinguishing characteristics,
including self-sufﬁciency in growth signaling, resistance to apop-
tosis, insensitivity to growth inhibitory signaling, sustained
angiogenesis, tissue invasion and metastasis, and limitless pro-
liferative potential. Many signaling proteins related to these
hallmarks of cancer are client proteins of Hsp90, such as Akt,
Her-2, p53, CDK4, Raf-1, IKK, HIF-1a, Src (Table 1). In
addition, the rapid growth of cancer cells requires the participa-
tion of large quantities of cytosolic heat shock proteins. Thus, it is
useful to inhibit cancer growth and metastasis by suppressing the
formation of complexes of Hsp90 and its client proteins, whichnot only reduces the tolerance of cancer cells to chemotherapeu-
tics, but also synergistically enhances the efﬁcacy of multiple
anticancer drugs. Hsp90 has been considered as a potent
molecular target in the development of new anticancer agents.
Since the ﬁrst natural anticancer drug vinblastine was applied in
clinic, many chemotherapeutic agents from natural products have
been discovered and developed, including paclitaxel, camptothe-
cin, epothilone, bleomycin and cantharidin, etc. Current Hsp90
inhibitors are derived from natural products, such as geldanamy-
cin, radicicol, novobicon, epigallocatechin-3-gallate, celastrol and
hypericin (Fig. 1). This review will brieﬂy describe the discovery
and development of natural product Hsp90 inhibitors.2. Inhibitors of Hsp90 N-terminal ATP binding domain
2.1. Geldanamycin (GA) and derivatives
Geldanamycin(1) (Fig. 1), originally isolated from the culture
ﬁltrates of Streptomyces hygroscopicus, inhibits the growth of
protozoa, bacteria and fungus8. GA was initially found to
arrest cancer cell proliferation by inhibiting Src tyrosine kinase,
but it was unable to directly inhibit the activity of puriﬁed
kinase9. Further studies revealed that the anti-proliferative
activity of GA resulted from the binding of GA to Hsp90.
GA inhibits client protein binding to Hsp90 through competi-
tive coupling with ATP/ADP binding ‘‘pocket’’ of the Hsp90
N-terminal domain, leading to the degradation of the client
proteins via the ubiquitination-proteasome pathway (Fig. 2).
The selectivity of GA for Hsp90 is due to the special ATP
binding ‘‘pocket’’ of Hsp90 as compared to other nucleotide-
binding proteins. Structure–activity analysis has revealed that
the 2,3-double bond of GA was indispensible for stable
conformation of Hsp90; 11-hydroxy and 17-methoxy moieties
contribute to formation of hydrogen bonds and increase the
binding afﬁnity of GA or its derivatives for Hsp90, thereby
leading to an enhancement of anticancer activities10. These
results suggest that the effectiveness of Hsp90 inhibitors is
closely related to their binding ability with Hsp90.
The structure of geldanamycin has been modiﬁed to reduce
its hepatotoxicity and increase its water-solubility. The site of
focus is the 17 position of the benzoquinone group to
generate more potent derivatives, including 17-allylamino-
17-demethoxy geldanamycin (17-AAG, 2) (Fig. 1) and
17-N,N-dimethylaminoethylamino-17-demethoxy geldanamycin
Figure 1 Chemical structures of Hsp90 inhibitors.
Yong Li et al.240(17-DMAG, 3) (Fig. 1) which are in phase II/III or I clinical
trials respectively (Table 2).
17-AAG (17-allyamino-17-demethoxygeldanamycin), in which
methoxymoiety of GA is replaced by an ally amino group, is the
ﬁrst Hsp90 inhibitor used in a clinical study with hepatotoxicity is
apparently less than that of geldanamycin. 17-AAG can be
metabolized by cytochrome P450 CYP3A4 to 17-amino-
demethoxygeldanamycin (17-AG) in vivo which maintains Hsp90
inhibitory activity and with higher stability than 17-AAG11. 17-
AAG binds to puriﬁed full-length dimeric Hsp90 in the low
micromolar range, whereas it inhibits tumor cell growth in the low
nanomolar range. This difference could be explained by theﬁnding that benzoquinone ansamycins largely accumulated in
tumor cells with high micromolar concentration12. Further studies
revealed that 17-AAG had a higher afﬁnity for Hsp90 derived
from the breast carcinoma cell line BT474 (IC50¼6 nM) than
Hsp90 from primary human renal epithelial cells (IC50¼600 nM
and 400 nM) and normal ﬁbroblasts (IC50¼400 nM). This
indicated that Hsp90 in tumor cells existed in the form of active
multi-chaperone complexes with Hsp70, Hsp40, Hop or p23,
whereas Hsp90 in normal cells was in an uncomplexed inactive
form13. In contrast to this suggestion, a recent study proposed
that the afﬁnity between GA and Hsp90 alone or the Hsp90
complex was similar, and that GA and its derivatives inhibited
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afﬁnity and low dissociation14. An alternative explanation was
also provided by Maroney et al.15, as they revealed that the
benzoquinone ring of ansamycins could be reduced to dihydro-
quinone by NAD(P)H: Quinone oxidoreductase 1. The reduced
product had approximately 40-fold greater afﬁnity for Hsp90
in vitro than its oxidized form and exhibited enhanced anticancer
activity, which contributed to the accumulation of ansamycin
dihydroquinones in cancer cells. Additionally, quantum chemi-
cal calculations and mutation analysis demonstrated that gelda-
namycin could undergo keto-enoltautomerization catalyzed by
Hsp90 which enhanced its binding to Hsp9016. It was also found
that Hsp90 did not catalyze the trans–cis isomerisation of GA
and conﬁrmed that the binding capability of the dihydroquinone
form of GA and its analogues to Hsp90 was more potent than
the afﬁnity of their oxidized quinone forms17.
17-AGG (oxidized form) entered clinical trials in 1999, and
its reduced form entered clinical trials in 2005. Further clinical
research and application of 17-AAG was limited due to itsFigure 2 Binding mode of GA to Hsp90.
Table 2 Hsp90 inhibitors in clinical trials.
Phase Indication
17-AAG II/III Multiple
II Pancreati
II Breast ca
II Melanom
II Kidney tu
17-DMAG I Solid tum
I Leukemia
Gambogic acid IIa Cancers
EGCG I Small cell
II Breast ca
II Prostate c
Curcumin II Pancreati
II Breast ca
I/II Osteosarc
aThis study is currently recruiting participants.poor solubility. 17-DMAG, a new generation of Hsp90
inhibitor developed by Kosan Biosciences, has better water
solubility, tissue dispersibility and bio-availability18. In com-
parison with 17-AAG, 17-DMAG possesses more potent
anticancer activity against many cell lines in vitro and
in vivo, and some scholars have suggested that this difference
might be attributed to the greater afﬁnity of Hsp90 for the
benzoquinone ansamycins or their metabolites19. Unfortu-
nately, 17-DMAG was also revealed to have gastrointestinal,
liver, bone marrow, renal and gallbladder toxicity in dogs20.
Thus, Kosan Biosciences stopped the clinical development of
17-DMAG in the beginning of 2008. However, the further
clinical tests are still being carried out by other research
groups because of its favorable water solubility and various
antitumor activities against different tumor types.
2.2. Herbimycin and its analogues
Herbimycin is also a member of benzoquinone ansamycin
antibiotics isolated from the culture ﬁltrates of Streptomyces
hygroscopicus. Herbimycin A (4) (Fig. 1) was primarily isolated
from the fermentation broth of Streptomyces hygroscopicus (No.
AM-3672)21, and later herbimycin B (5), C (6) (Fig. 1) and
dihydroherbimycin were obtained. Herbimycin was a selective
inhibitor of a tyrosine kinase, and had an inhibitory effect on
cancer angiogenesis and proliferation22,23. Yang et al.24 have
compared the anti-proliferative activities of herbimycin analogues
on Vero and B16-F10 cells as follows: herbimycin C4herbimycin
A4dihydroherbimycin A (7) (Fig. 1). Further studies suggested
that the underlying anti-tumor mechanism was also competitive
binding to the N-terminal domain of Hsp90 to arrest the ATPase
cycle25. To date there is no clinical report on herbimycin and its
analogues.
2.3. Radicicol (RA) and its analogues
Radicicol (8) (Fig. 1) belongs to the macrocyclic lactone anti-
biotics originally extracted from the ﬁltrate of fungus Monospor-
iumbonorden. It can inhibit cancer cell proliferation andNCT ID
myeloma NCT00514371, NCT00546780
c cancer NCT00577889
ncer NCT00096109, NCT00118092
a NCT00087386 NCT00088374
mor
or NCT00088868, NCT00089362
lymphoma NCT01126502a
2004L00333(SFDA)
lung cancer NCT01317953a
ncer NCT00917735a
ancer NCT00676780, NCT00596011a
c cancer NCT00192842
ncer NCT01042938
oma NCT00689195a
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protein kinase and disruption of K-ras-activated aberrant signal-
ing pathways26–28. Similar to benzoquinone ansamycins, it can
also competitively bind to the N-terminal domain of Hsp90 to
disrupt Hsp90 complex formation29. Results from isothermal
titration calorimetry suggested that the afﬁnity of radicicol to
Hsp90N was about 50-fold greater than that of geldenamycins10.
Radicicol showed more potent antitumor activity than geldena-
mycins in vitro, but weaker activity in vivo, which could be
explained by the fact that the presence of epoxy and a, b, g, d-
unsaturated carbonyl groups reduced the stability of radicicol30.
Structure–activity relationship analysis indicated that the
benzene hydroxyl and macrocyclic ring were required for
biological activity of radicicol31. A series of stable radicicolox-
ime derivatives have been synthesized by means of reducing the
nucleophilicity of unsaturated carbonyl groups. Soga et al.32,33
have indicated that KF25706 (9) (Fig. 1) could selectively
deplete the client proteins of Hsp90 via inhibition of v-Src and
K-ras-activated signaling pathways and KF58333 (10) (Fig. 1)
could suppress VEGF expression and tumor angiogenesis
through an HIF-1a-dependent pathway. These results indicate
that the oxime moiety plays a signiﬁcant role in sustaining the
stability and enhancing the biological activity of radicicoloxime
analogues. In contrast to geldanamycin and its derivatives,
radicicol has no hepatotoxicity, which implies that hepatotoxi-
city of benzoquinone ansamycins is not a common characteristic
of all Hsp90 inhibitors34. Thus, radicicol and its analogues are
promising drug candidates for further development as non-
benzoquinone ansamycin Hsp90 inhibitors. Unfortunately, there
is no clinical report of these compounds to date.2.4. Gambogic acid
Gambogic acid (11) (Fig. 1) is the main component of
gamboge used for treating tumors or infections. It has been
reported that gambogic acid was an inhibitor of Hsp90
through binding to the N-terminal domain of Hsp90 in a
non-competitive manner similar to that of geldanamycin35. A
phase IIa clinical trial to explore tolerability and safety of
gambogic acid in cancer patients via different intravenous
administration methods was completed in 2008 in China
(Table 2).3. Inhibitors of Hsp90 C-terminal ATP-binding domain
3.1. Novobiocin and analogues
Novobiocin (12) (Fig. 1), a coumarin antibiotic isolated from
several Streptomyces strains, exhibited anti-bacterial activity
through binding with topoisomerase II to inhibit ATP hydro-
lysis36. Given that Hsp90 is also an ATPase-dependent
protein, novobiocin might be also an inhibitor of Hsp90.
Novobiocin interacted with the Hsp90C ATP-binding domain
to disrupt Hsp90 dimerization and induce conformational
changes of the Hsp90 complex, ﬁnally leading to the degrada-
tion of client proteins via the ubiquitination-proteasome
pathway. However, novobiocin at a concentration of
700 mM induced depletion of Hsp90 clients in SKBr3 cells,
which was much weaker than Hsp90N inhibitors including
benzoquinone ansamycins and radicicol analogues37. Furtherreasonable modiﬁcations should be carried out to enhance the
bioactivity of novobiocin.
The structure of novobiocin is composed of three domains,
including benzamide moiety, a coumarin moiety and noviose
moiety. Blagg et al.38 have synthesized a series of analogues
and elucidated their structure–activity relationships: 3-second-
ary amine and 7-noviose moieties were indispensable for their
bioactivities; 8-methoxy was useful to increase the bioactivity
but 5-substitution may decrease the bioactivity; and the
coumarinlactone moiety was not critical for Hsp90 inhibition.
4-Hydroxyl and 3’-carbamate of noviose moieties could impair
the inhibitory activity towards Hsp90 but were essential for
inhibition of DNA topoisomerase39. In contrast to Blagg’s
reports, Renoir et al.40 found that antitumor activities of these
derivatives were signiﬁcantly enhanced through substituting a
tosyl moiety at C-4 or C-7 position of coumarin rings and
highlighted that C-4 and/or C-7 positions of coumarin may be
required for degradation of Hsp90 client proteins. Currently,
novibiocon has mainly been used to treat bacterial infection in
the clinic.
3.2. ()-Epigallocatechin-3-gallate (EGCG)
()-Epigallocatechin-3-gallate (EGCG) (13) (Fig. 1) is a major
polyphenolcatechin of green tea and possesses excellent anti-
tumor activity, although its mechanism has not yet been
clariﬁed. Palermo et al.41 ﬁrst reported EGCG could inhibit
aryl hydrocarbon receptor binding of Hsp90. Furthermore, Li
et al.42 proposed that EGCG may disrupt the association of
Hsp90 with co-chaperone Hsc70 and p23 via direct binding to
the Hsp90 C-terminal domain, and degrade Hsp90-related
client proteins including Akt, Cdk4, Raf-1, Her-2 and pERK.
Additionally, EGCG was also proven to be able to inhibit the
growth and development of tumors in vitro and in vivo by
suppressing the expression of Hsp70 and Hsp9043. Gasiewicz
et al.44 suggested that EGCG directly inhibited the dimeriza-
tion and modulated the conformation of Hsp90 by binding at
or adjacent to the C-terminal ATP-binding site, just not as
N-terminal Hsp90 inhibitors with destabilization of the Hsp90
complex. These reports indicate that EGCG could treat
various tumors and enhance the anti-cancer activity of
chemotherapeutics. Recently, a phase I clinical trial is testing
the safety of EGCG for extensive-stage small lung cancer in
those who achieved the objective tumor response after ﬁrst-
line therapy (Table 2).4. Inhibitors of Hsp90 and interaction with co-chaperones
Co-chaperones play a signiﬁcant role in modulating the
formation and maturation of Hsp90 and its client proteins.
The cell division cycle protein 37 (CDC37) is an important co-
chaperone, which helps the efﬁcient recruitment of client
proteins (mainly protein kinases) to the chaperone machinery
and facilitates the formation of mature client proteins. There-
fore, inhibition of CDC37/Hsp90 complex may efﬁciently
decrease the expression of client proteins in cancer cells.
Celastrol (14) (Fig. 1), also called tripterine, was isolated
from the root extracts of Thunder God Vine which is used to
treat inﬂammatory and autoimmune diseases (e.g., rheuma-
toid arthritis, sclerosis and systemic lupus erythematosus) in
traditional Chinese medicine. It was recently reported to
Figure 3 Binding mode of celastrol to Hsp90/CDC37.
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celastrol showed an anti-pancreatic cancer effect in vitro and
in vivo through disruption of the interaction of CDC37 with
Hsp90 without affecting ATP binding to Hsp90, thereby
inducing the degradation of Hsp90 client proteins (Fig. 3).
According to results from 1H, 15N-HSQC NMR, the thiol
group of CDC37 N-terminal may react with the quinone-
methide of celastrol through a Michanel addition at the C6
position, resulting in a change of CDC37 conformation and
disruption of the Hsp90 complex formation. In addition, there
is a large hydrophobic core at the interface of CDC37/Hsp90
complex and celastrol could disrupt the hydrophobic core at
C293 and block the formation of Hsp90/CDC37 complex.
Thus, the N-terminal of CDC37 and the middle domain may
be the main interaction sites of celastol47. Extracts of Thunder
God Vineis used to treat rheumatoid arthritis, Crohn’s disease
and immunological rejection of kidney transplantation in IIb
clinical trials, whereas the anti-tumor effect of celastrol has
been studied only in preclinical tests.
Derrubone (15) (Fig. 1) is a natural prenylated isoﬂavone
originally isolated from Derris robusta. In high-throughput
screening, Blagg et al.48 discovered that it induced potent cell
growth inhibition and Her2 degradation in human breast cells
(MCF-7 and SkBr3) without describing its speciﬁc mechanism.
Furthermore, they synthesized chimeric analogues of novibio-
cin and derrubone sharing several key structural features, and
evaluated their bioactivities. They also found that the iso-
ﬂavone motif of derrubone and the coumarin moiety of
vovibiocin exerted different modes of action on binding to
Hsp90, however, the C-3 position of the bicyclic ring of both
was required for inhibiting Hsp9049. Derrubone, as a lead
Hsp90 inhibitor, is expected to have a promising development.
Curcumin (16) was isolated from Zingiberaceae family
plants, including Curcuma aromatica, Curcuma longa and
Curcuma phaeocaulis. It possesses anti-oxidant, anti-inﬂam-
matory and anti-tumor activities. Curcumin can also induce
apoptosis in cancer cells by different signaling pathways and
markedly enhance the sensitization of cells to other anticancer
drugs50. Jung et al.51 found that curcumin induced degrada-
tion of ErbB2 (a client of Hsp90), suggesting that Hsp90 or anHsp90 complex may be a target of curcumin. Lee et al.52
indicated that curcumin treatment resulted in dissociation of
the Hsp90/p23 complex from human telomerase reverse
transcriptase (hTERT), down-regulation of hTERT expres-
sion and inhibition of nuclear localization of telomerase to
modulate the growth and development of cancer. Giommarelli
et al.53 observed that curcumin could directly inhibit Hsp90
and facilitate dissociation of client proteins (EGFR, Akt,
surviving and Raf-1) from Hsp90 complexes. But given that
curcumin had a low afﬁnity for Hsp90 and led to the down-
regulation of Hsp70, it was indicated that the mechanism
behind its Hsp90 inhibitory effect may be not identical to that
of 17-AAG. In addition, it could also enhance the sensitivity
of tumor cells to HDAC inhibitors and synergistically induce
cellular growth inhibition and apoptosis. These results suggest
that curcumin may be a promising agent to treat cancers in
clinic. Currently, several clinical trials have been reported in
the treatment of colorectal cancer, rectal cancer and pancreatic
cancer (Table 2). Unfortunately, the application of curcumin
in the clinic was limited owing to its poor bioavailability. It is
anticipated that structural modiﬁcations will markedly
improve its bioavailability and antitumor activity.5. Other Hsp90 inhibitors
Tubocapsenolide A (17) (Fig. 1), a member of withanolide
compounds, was isolated from Tubocapsicum anomalum. It could
selectively induce thiol oxidation of Hsp90 and Hsp70 to
destabilize and degrade Hsp90 client proteins, leading to cell
cycle arrest and apoptosis in breast cancer MDA-MB-231 cells54.
Hypericin (18) (Fig. 1) was isolated from the European
plant Hypericum perforatum, which is used in anti-virus and
anti-tumor treatments. Blank et al.55 proposed that hypericin
enhanced ubiquitinylation of Hsp90 to degrade Hsp90 client
proteins. Phase I/II or II clinical trials have been conducted to
test the effectiveness, safety, and tolerance of hypericin for
patients with recurrent malignant gliomas or cutaneous T-cell
lymphaomas, as well as psoriasis.
Gedunin (19) (Fig. 1) was derived from the Indian neem
tree (Azadirachta indica). Hieronymus et al.56 reported that
gedunin modulated Hsp90 to inhibit proliferation of cancer
cells, but it did not competitively bind to the Hsp90 ATP-
binding pocket as seen with geldanamycin. Blagg et al.57
synthesized 19 gedunin analogues in an effort to elucidate
the structure–activity relationships of the gedunin–Hsp90
interaction. Unfortunately, anti-proliferative activities of these
derivatives were much lower than that of gedunin in breast
cancer cell lines MCF-7 and SkBr3. Further study is underway
to obtain more gedunin analogues with potent chemothera-
peutic properties.6. Conclusions
A signiﬁcant hallmark of cancer cells in the process of growth
and development is inﬁnite proliferation and immortalization,
which requires associated chaperones for regulating protein
synthesis. Studies also ﬁnd Hsp90 and co-chaperones are
abnormally expressed in cancer cells, thus it is expected that
the identiﬁcation and development of Hsp90 inhibitors will
have a promising future. However, whether Hsp90 inhibitors
Yong Li et al.244also inﬂuence Hsp90 function in normal cells while they
inhibit Hsp90 and Hsp90 complexes of tumor cells remains
to be determined. Some studies have shown that 17-DMAG is
widely distributed in different tissues, but it is unclear why it is
metabolized much more slowly in cancer cells than normal
cells58. The afﬁnity of ansamycins for Hsp90 in cancer cells is
apparently 20–50 times stronger than it is in normal cells. This
may be explained by the idea that Hsp90 in cancer cells is in
the form of multi-chaperone complexes that modulate client
protein maturation, while Hsp90 in normal cells is in an
uncoupled inactive form. Another explanation is that the
ATPase activity of Hsp90 in tumor cells is markedly higher
than that in normal cells13. Nevertheless, the molecular
mechanisms of interaction of Hsp90 inhibitors with Hsp90
warrants further study.
Most chemotherapeutics have serious side effects, such as
geldanamycin and its derivatives demonstrating hepatotoxicity,
poor solubility, nausea and vomiting in clinical use. In China,
traditional Chinese medicines in cancer treatment offer unique
advantages and are widely accepted and used in the clinic. The
multiple effects of Hsp90 inhibitors on the treatment of tumor
are consistent with the characteristics of traditional Chinese
medicines in which multi-level, multi-target approaches are
valued. Therefore, natural Hsp90 inhibitors can be useful in
the enhancement of antitumor activity and decreased toxicity
and resistance to drugs when combined with other chemother-
apeutic agents. Hsp90 inhibitors have been isolated from
Chinese herbs and yielded multiple bioactive constituents,
including curcumin, hypericin, celastrol, etc. Although the
biological activities of these compounds are less than those of
geldanamycin and its analogues, their toxicities are also lower.
Furthermore, these compounds not only enrich the chemical
structure library of Hsp90 inhibitors, but also provide lead
compounds for further synthesis of more selective and less toxic
Hsp90 inhibitors. It is anticipated that the focus on discovery
and development of Hsp90 inhibitors from traditional Chinese
medicines through chemical separation and computer-aided
drug design combined with high-throughput screening technol-
ogy will yield further success in the development of Hsp90
inhibitors for use in cancer.
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